| Patent Number |
Title Of Patent |
Date Issued |
| 8124057 |
Propellant-based nanoparticulate dry powder aerosols and method of making |
February 28, 2012 |
| There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The na |
| 7763278 |
Nanoparticulate polycosanol formulations and novel polycosanol combinations |
July 27, 2010 |
| The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosan |
| 7695739 |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or |
April 13, 2010 |
| Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions. |
| 7585517 |
Transscleral delivery |
September 8, 2009 |
| Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these |
| 7521068 |
Dry powder aerosols of nanoparticulate drugs |
April 21, 2009 |
| There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The na |
| 7390505 |
Nanoparticulate topiramate formulations |
June 24, 2008 |
| The present invention is directed to nanoparticulate compositions comprising topiramate. The topiramate particles of the composition have an effective average particle size of less than about 2 microns. |
| 7198795 |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of |
April 3, 2007 |
| Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions. |
| 6908626 |
Compositions having a combination of immediate release and controlled release characteristics |
June 21, 2005 |
| Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of th |
| 6811767 |
Liquid droplet aerosols of nanoparticulate drugs |
November 2, 2004 |
| There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The na |
| 5853713 |
Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
December 29, 1998 |
| A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs. |
| 5705194 |
Pharmaceutical compositions containing polyalkylene block copolymers which gel at physiological |
January 6, 1998 |
| There is disclosed a pharmaceutical composition which gels at physiological temperature. The composition is comprised of a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy (higher alkylene) blocks wherein at least some of the blocks are linked togethe |
| 5620677 |
Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointesti |
April 15, 1997 |
| Disclosed are contrast agents of the formula ##STR1## contained in aqueous compositions and methods for their use in diagnostic radiology of the gastrointestinal tract whereinZ=H, halo, C.sub.1 -C.sub.20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups ca |
| 5618528 |
Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
April 8, 1997 |
| A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs. |
| 5585108 |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically ac |
December 17, 1996 |
| Nanoparticulate crystalline therapeutic substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect. |
| 5565188 |
Polyalkylene block copolymers as surface modifiers for nanoparticles |
October 15, 1996 |
| There is disclosed a composition containing nanoparticles having a surface modifier wherein the surface modifier is a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy(higher alkylene) blocks wherein at least some of the blocks are linked together by a |
| 5531979 |
Compositions of iodophenoxy alkanes and iodophenyl ethers and pharmaceutically acceptable clays |
July 2, 1996 |
| Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising iodophenoxy alkanes and iodophenyl ethers as the x-ray producing agents in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; |
| 5484585 |
Compositions of iodobenzoic acid derivatives and pharmaceutically acceptable clays for visualiza |
January 16, 1996 |
| Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising iodobenzoic acid derivatives as the x-ray producing agents in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and method |
| 5472682 |
Compositions of iodophenyl esters and iodophenyl sulfonates and pharmaceutically acceptable clay |
December 5, 1995 |
| Disclosed are x-ray contrast compositions of the formula ##STR1## wherein X is ##STR2## or --SO.sub.2 --; Z is H, halo, methyl, ethyl, n-propyl, C.sub.4 -C.sub.20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups can be substituted with halogen or |
| 5466440 |
Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharm |
November 14, 1995 |
| Nanoparticulate crystalline substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline substances and the gastrointestinal tract. These formulations have improved safety profiles, a low potential for absorption, are not vis |
| 5466440 |
Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharm |
November 14, 1995 |
| Nanoparticulate crystalline substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline substances and the gastrointestinal tract. These formulations have improved safety profiles, a low potential for absorption, are not vis |
| 5451393 |
X-ray contrast compositions useful in medical imaging |
September 19, 1995 |
| An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, an |
| 5424056 |
X-ray contrast compositions containing iodoaniline derivatives and pharmaceutically acceptable c |
June 13, 1995 |
| Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising an iodoaniline derivative as the x-ray producing agent in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and methods fo |
| 5368837 |
X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulo |
November 29, 1994 |
| Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a crystalline contrast agent in a pharmaceutically acceptable carrier comprising a cellulose derivative; and methods for their use in diagnostic radiology of the gast |
| 5360604 |
X-ray contrast compositions containing an organic crystalline X-ray contrast agent in combinatio |
November 1, 1994 |
| Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a crystalline organic constrast agent in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and methods for their use in di |
| 5326553 |
Compositions of iodophenoxy alkanes and iodophenyl ethers in film-forming materials for visualiz |
July 5, 1994 |
| Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a polymeric material capable of forming a coating on the gastrointestinal tract and an x-ray producing agent of the formula ##STR1## and methods for their use in |
| 5318768 |
Polymeric x-ray contrast compositions containing an organic crystalline x-ray contrast agent |
June 7, 1994 |
| Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a polymeric material in combination with a divalent cation capable of forming a coating on the gastrointestinal tract and a crystalline contrast agent in a pharmaceut |
| 5318767 |
X-ray contrast compositions useful in medical imaging |
June 7, 1994 |
| An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, an |
| 5316755 |
Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointesti |
May 31, 1994 |
| Disclosed are contrast agents of the formula ##STR1## contained in aqueous compositions and methods for their use in diagnostic radiology of the gastrointestinal tract whereinZ=H, halo, C.sub.1 -C.sub.20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups ca |
